Rankings
▼
Calendar
LGND Q1 2025 Earnings — Ligand Pharmaceuticals Incorporated Revenue & Financial Results | Market Cap Arena
LGND
Ligand Pharmaceuticals Incorporated
$4B
Q1 2025 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$45M
+46.3% YoY
Gross Profit
$40M
89.3% margin
Operating Income
-$36M
-79.9% margin
Net Income
-$42M
-93.6% margin
EPS (Diluted)
$-2.21
QoQ Revenue Growth
+5.9%
Cash Flow
Operating Cash Flow
-$26M
Free Cash Flow
-$26M
Stock-Based Comp.
$0
Balance Sheet
Total Assets
$905M
Total Liabilities
$110M
Stockholders' Equity
$796M
Cash & Equivalents
$48M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$45M
$31M
+46.3%
Gross Profit
$40M
$20M
+103.3%
Operating Income
-$36M
$3M
-1312.0%
Net Income
-$42M
$86M
-149.3%
Revenue Segments
Royalty
$27M
35%
Intangible Royalty Assets
$22M
27%
Material Sales, Captisol
$13M
17%
Financial Royalty Assets
$6M
7%
Kyprolis
$5M
6%
Rylaze
$3M
4%
Evomela
$2M
2%
Teriparatide Injection
$1M
1%
← FY 2025
All Quarters
Q2 2025 →